Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study

  • Yukari Suzuki
  • , Kei Saito
  • , Yousuke Nakai
  • , Hiroki Oyama
  • , Sachiko Kanai
  • , Tatsunori Suzuki
  • , Tatsuya Sato
  • , Ryunosuke Hakuta
  • , Kazunaga Ishigaki
  • , Tomotaka Saito
  • , Tsuyoshi Hamada
  • , Naminatsu Takahara
  • , Ryosuke Tateishi
  • , Mitsuhiro Fujishiro

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospective observational study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science